News

In our previous blog we discussed how analyses of the impact of H.R. 3 published by the Congressional Budget Office (CBO) do not reflect the process of investing. Here, the third blog in our Series, we discuss another problem with their analysis: how they measure the output of innovation.

Our second blog in the OHE H.R. 3 Series discusses how the Congressional Budget Office (CBO)’s analysis of H.R.3 does not reflect the reality of biopharmaceutical investing.

This year’s iHEA Congress takes place virtually from July 12th to July 15th, 2021, and is titled “Health Economics in a Time of Global Change”. Take a look at OHE’s speaking engagements!

Pages